NCT04562311 is a Phase 2 clinical trial of Chidamide in Bladder Cancer Stage IV, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04562311?

NCT04562311 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04562311?

Interventions in NCT04562311: Chidamide.

What condition does NCT04562311 study?

NCT04562311 studies Bladder Cancer Stage IV.

Is NCT04562311 still recruiting?

NCT04562311 is currently active, enrolled. Last updated 4 December 2024.

Last reviewed 2024-12-04 · How we verify

NCT04562311

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Active, enrolled Phase 2 Last updated 4 December 2024

What this trial tests

Phase 2 trial testing Chidamide in Bladder Cancer Stage IV in 45 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2021

Primary endpoint
30 August 2024

30 October 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	1 January 2021
Primary completion	30 August 2024
Estimated completion	30 October 2025
Sites	1 location across China

Drugs / interventions tested

Chidamide — full drug profile →

Conditions studied

Bladder Cancer Stage IV — all drugs for Bladder Cancer Stage IV →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Bladder Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E, Zhu Z, Wahed S, Qu Z, et al · · 2021 · cited 224× · PMID 34930302 · DOI 10.1186/s12943-021-01464-x
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing.
Majchrzak-Celińska A, Warych A, Szoszkiewicz M. · · 2021 · cited 85× · PMID 33572577 · DOI 10.3390/genes12020208
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy.
Leblond MM, Zdimerova H, Desponds E, Verdeil G. · · 2021 · cited 54× · PMID 34572939 · DOI 10.3390/cancers13184712
Epigenetic modifications in diabetes.
Kowluru RA, Mohammad G. · · 2022 · cited 46× · PMID 34715117 · DOI 10.1016/j.metabol.2021.154920
Metastatic Urothelial Cancer: a rapidly changing treatment landscape.
Stecca C, Abdeljalil O, Sridhar SS. · · 2021 · cited 40× · PMID 34616491 · DOI 10.1177/17588359211047352
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy.
Chen C, Wang Z, Qin Y. · · 2022 · cited 35× · PMID 35935878 · DOI 10.3389/fphar.2022.935536
Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.
Xu Y, Li P, Liu Y, Xin D, et al · · 2022 · cited 29× · PMID 35642676 · DOI 10.1002/cac2.12313

Verify or expand the search:

Other trials of Chidamide

Trials testing the same drug.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07415980 — Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients · Phase 1, PHASE2 · not yet recruiting
NCT07507318 — Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04562311 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 4 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04562311.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing